mdm28 Antibody

What is MED28 and what cellular functions is it involved in?

MED28 is a protein that functions in multiple cellular processes including transcription, signal transduction, and cell proliferation. Research has demonstrated that MED28 plays significant roles in both nuclear and cytoplasmic compartments. In the nucleus, it participates in transcriptional regulation as part of the mediator complex, while in the cytoplasm, it contributes to signaling pathways that influence cellular growth . Overexpression of MED28 has been associated with tumor progression in both in vitro and in vivo models, suggesting its potential role in oncogenesis . Recent studies have particularly highlighted the correlation between elevated MED28 expression and poor outcomes in breast cancer patients .

What applications can MED28 antibodies be used for?

MED28 antibodies have been validated for multiple laboratory applications, each with specific optimization requirements:

• Western Blotting (WB): MED28 antibodies can detect both endogenous and exogenously expressed MED28 protein in various cell types, including human and mouse cell lines .

• Immunohistochemistry (IHC): Specific antibody clones (notably 3B2, 9G5, and 10D4) have shown efficacy in paraffin-embedded tissue sections, primarily detecting MED28 in nuclear and partially in cytoplasmic locations .

• Immunofluorescence (IF): MED28 antibodies can visualize the protein's localization in both fixed cells and tissues, confirming its presence in both nuclear and cytoplasmic compartments .

• Immunoprecipitation (IP): Several monoclonal antibodies have demonstrated the ability to efficiently immunoprecipitate both endogenous and exogenously expressed MED28 protein .

The recommended dilutions vary by application, with ranges typically being 1:250-1:500 for Western blot and 1:50-1:200 for immunohistochemistry .

What is the difference between polyclonal and monoclonal MED28 antibodies?

The key differences between polyclonal and monoclonal MED28 antibodies relate to their specificity, consistency, and applications:

Polyclonal MED28 antibodies:

• Generated in animals (typically rabbits) immunized with MED28 protein or peptides

• Recognize multiple epitopes on the MED28 protein

• Offer high sensitivity but potentially lower specificity

• May show batch-to-batch variation

• Often used for applications requiring higher sensitivity, such as detecting low-abundance proteins

Monoclonal MED28 antibodies:

• Produced from hybridoma cell lines derived from a single B-cell clone

• Recognize a single epitope on the MED28 protein

• Provide consistent results with minimal batch variation

• Often demonstrate higher specificity but potentially lower sensitivity

• Generated through a more complex process involving mouse immunization, cell fusion, and hybridoma selection

• Available in specific clones (e.g., 3B2, 4F11, 9G5, 10D4) with distinct characteristics for different applications

Where is MED28 localized in cells?

Immunofluorescence and immunohistochemical studies using MED28 antibodies have revealed that MED28 exhibits both nuclear and cytoplasmic localization . This dual localization pattern is consistent with MED28's multiple functional roles in the cell. In the nucleus, MED28 primarily functions as part of the mediator complex involved in transcriptional regulation . In the cytoplasm, it participates in signaling pathways related to cell proliferation .

Specifically, immunofluorescence staining in MCF-7 cells using monoclonal antibodies has clearly demonstrated this dual localization pattern . Additionally, immunohistochemical analyses of human breast cancer tissues showed that MED28 was "mainly localized in the nucleus and partly in cytoplasm" . This subcellular distribution pattern may vary slightly depending on cell type, physiological state, and experimental conditions.

What are the optimal protocols for using MED28 antibodies in Western blotting?

For optimal Western blot results with MED28 antibodies, researchers should follow these methodological guidelines:

Sample preparation:

• Lyse cells using a buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM EDTA, with protease inhibitors (1 mM PMSF, 10 mM NaF, 0.1 mM NaVO3)

• Load approximately 30 μg of whole cell lysate per well on a 13% reducing SDS-PAGE gel

Blotting and detection:

• Transfer proteins to PVDF membrane using semi-dry method

• Block the membrane with TBS containing 5% skim milk and 0.5% Tween-20 for 1 hour at room temperature

• Incubate with primary MED28 antibody at a dilution of 1:250-1:500 (for polyclonal) or 1:10,000 (for concentrated monoclonal ascites) for 2 hours at room temperature

• Wash twice with TBST (TBS containing 0.27% Tween-20)

• Incubate with HRP-conjugated secondary antibody (1:20,000 dilution) for 1 hour at room temperature

• Wash three times with TBST and develop using enhanced chemiluminescence (ECL) solution

Expected results:

• Endogenous MED28 should appear as a band at approximately 22 kDa

• Exogenously expressed tagged MED28 will show bands at higher molecular weights depending on the tag (e.g., GFP-MED28 at ~45 kDa)

How can I optimize immunoprecipitation with MED28 antibodies?

Successful immunoprecipitation of MED28 requires attention to several methodological details:

For endogenous MED28 immunoprecipitation:

• Start with approximately 1 mg of total protein extract from cells expressing MED28 (e.g., HEK293)

• Incubate cell lysate with 2 μg of purified MED28 IgG for 4 hours

• Add protein G agarose beads and continue incubation for an additional 2 hours

• Wash extensively to remove non-specifically bound proteins

• Elute bound proteins and analyze by SDS-PAGE

• Detect MED28 by Western blotting using another MED28 antibody (ideally recognizing a different epitope)

For exogenously expressed MED28:

• Transfect cells with tagged MED28 constructs (GFP-MED28 is preferable to avoid IgG light chain overlap)

• Use 0.2 mg of protein extract for immunoprecipitation

• Follow the same procedure as for endogenous IP

• Confirm results with appropriate controls, including:

  • IgG isotype control to assess non-specific binding

  • Input sample (pre-IP lysate) to verify target protein expression

  • Non-transfected cells as a negative control for exogenous IP

The monoclonal antibody clones 3B2, 4F11, 9G5, and 10D4 have all demonstrated efficient immunoprecipitation of both endogenous and exogenously expressed MED28 protein .

What are the considerations for using MED28 antibodies in immunohistochemistry?

When performing immunohistochemistry with MED28 antibodies, researchers should address these key methodological considerations:

Tissue preparation and antigen retrieval:

• Use formalin-fixed, paraffin-embedded (FFPE) tissue sections at approximately 5 μm thickness

• Perform deparaffinization and rehydration through xylene and graded alcohols

• Quench endogenous peroxidase activity with methanol/peroxidase solution

• Use appropriate antigen retrieval methods (typically heat-induced epitope retrieval)

Antibody selection and staining protocol:

• Not all MED28 antibody clones work equally well for IHC; clones 3B2, 9G5, and 10D4 have demonstrated good performance, while clone 4F11 was not applicable for IHC

• Use antibody at a dilution of approximately 1:50-1:200 or 1:100 for monoclonal antibodies

• Employ detection systems compatible with the primary antibody (e.g., DAB detection kit)

• Counterstain with Mayer's hematoxylin to visualize nuclei

Interpretation of results:

• Expect to see MED28 staining primarily in the nucleus and partially in the cytoplasm

• Observe moderate cytoplasmic and nuclear membranous positivity in specific cell types such as neurons

• Include appropriate positive and negative controls

• Assess staining intensity and distribution patterns in relation to clinical parameters when studying disease tissues

Different tissue types may require optimization of these protocols, particularly regarding antigen retrieval methods and antibody dilutions.

How can I troubleshoot non-specific binding when using MED28 antibodies?

Non-specific binding is a common challenge when working with antibodies, including those against MED28. Several methodological approaches can help minimize this issue:

For Western blotting:

• Increase the blocking time or concentration of blocking agent (5-10% milk or BSA)

• Optimize primary antibody dilution (try a range from 1:250 to 1:1000)

• Increase the number or duration of washing steps with TBST

• Try different blocking agents (milk vs. BSA) as some antibodies perform better with specific blockers

• Check if the non-specific bands appear in negative control samples lacking MED28 expression

• Consider using a different clone if one consistently shows higher specificity (e.g., clones 3B2, 9G5, and 10D4 have demonstrated good specificity)

For immunohistochemistry and immunofluorescence:

• Pre-absorb the antibody with recombinant MED28 protein to reduce non-specific binding

• Include appropriate controls (isotype control antibodies, tissues known to be negative for MED28)

• Optimize antibody concentration, starting with manufacturer's recommended dilution (1:50-1:200)

• Increase washing steps between antibody incubations

• Use more stringent blocking with normal serum from the same species as the secondary antibody

General considerations:

• Verify antibody specificity through knockout/knockdown experiments

• Consider using monoclonal antibodies which typically show lower non-specific binding than polyclonals

• Be aware that generating high-quality MED28 antibodies is challenging "due to non-specific background"

• If possible, validate results with multiple antibody clones recognizing different epitopes

How does MED28 expression correlate with clinical outcomes in cancer?

Research has established significant correlations between MED28 expression patterns and clinical outcomes, particularly in breast cancer:

• Elevated expression of MED28 has been associated with poor outcomes in women with breast cancer

• MED28 overexpression stimulates cell proliferation in both in vitro and in vivo experimental models

• Suppression of MED28 has been shown to inhibit the growth and tumorigenicity of breast cancer cells

• Quantify MED28 expression levels using both protein (IHC, Western blot) and mRNA analyses

• Correlate expression patterns with clinicopathological features

• Assess MED28 localization patterns, as alterations in nuclear versus cytoplasmic distribution may have functional significance

• Consider MED28 in the context of other established biomarkers

What techniques can be used to study MED28 protein-protein interactions?

Understanding MED28's interactions with other proteins is crucial for elucidating its functions in both normal and disease states. Several methodological approaches can be employed:

Immunoprecipitation-based methods:

• Co-immunoprecipitation (Co-IP) using MED28 antibodies to pull down interacting proteins

• Reverse Co-IP using antibodies against suspected interacting partners

• Tandem affinity purification (TAP) with tagged MED28 constructs

Mass spectrometry approaches:

• Immunoprecipitate MED28 and identify binding partners through mass spectrometry

• Proximity-based labeling methods (BioID or APEX) with MED28 fusion proteins

• Cross-linking mass spectrometry to capture transient interactions

Imaging-based techniques:

• Fluorescence co-localization studies using MED28 antibodies

• Förster resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC)

• Proximity ligation assay (PLA) to visualize protein-protein interactions in situ

Protein-protein interaction studies are particularly relevant as "med28 might be regulated by a variety of molecules and also regulate its downstream targets to exert its function" . The availability of high-quality monoclonal antibodies provides valuable tools for investigating these interactions through techniques like immunoprecipitation.

How are MED28 monoclonal antibodies generated and characterized?

The generation of MED28 monoclonal antibodies follows a systematic process with several critical steps:

Antigen preparation:

• The MED28 gene (encoding 178 amino acids) is amplified from cDNA libraries and inserted into bacterial expression vectors (e.g., pET28a)

• Recombinant protein is expressed in E. coli with induction by IPTG (0.1 mM at 30°C for 4 hours)

• Proteins are purified through nickel affinity chromatography using denaturation and renaturation methods

• Purified protein with >93% purity is used for immunization

Immunization and hybridoma generation:

• Female BALB/C mice (13 weeks old) are immunized subcutaneously with recombinant MED28 protein (200 μg) mixed with complete Freund's adjuvant

• Boosting injections are administered at 3-4 week intervals

• Antibody titers are assessed using indirect ELISA

• Splenocytes from mice showing high immune response are fused with SP2/0 myeloma cells to generate hybridomas

• Hybrid cells are selected using HAT medium and screened for antibody production

• Positive hybridomas are subcloned by limiting dilution to ensure monoclonality

Characterization of antibodies:

• Isotyping is performed to determine antibody class (e.g., IgG1, kappa)

• Specificity is validated through multiple applications including:

  • Western blotting with both endogenous and exogenously expressed MED28

  • Immunoprecipitation of native proteins

  • Immunofluorescence microscopy to confirm cellular localization

  • Immunohistochemical analyses of relevant tissues

This rigorous process has yielded four well-characterized monoclonal antibody clones (3B2, 4F11, 9G5, and 10D4) with defined properties for various research applications .

What are the advantages and limitations of different MED28 antibody clones?

Different monoclonal antibody clones against MED28 exhibit distinct characteristics that make them suitable for specific applications:

Advantages of using monoclonal antibodies:

• High specificity with minimal non-specific binding

• Consistent performance across different lots

• Defined epitope recognition

Limitations to consider:

• Some clones may not work for all applications (e.g., clone 4F11 is not suitable for IHC)

• Epitope accessibility may vary depending on protein conformation or experimental conditions

• Different fixation methods may affect antibody performance in immunofluorescence and IHC

When selecting a MED28 antibody clone, researchers should consider:

• The specific application requirements

• The species and cell type being studied

• Whether detecting endogenous or exogenously expressed MED28 is required

• The importance of detecting MED28 in specific subcellular compartments

What are emerging research areas utilizing MED28 antibodies?

Several promising research directions are emerging for MED28 antibodies:

• Cancer biomarker development:

  • Using MED28 antibodies to assess expression patterns across tumor types

  • Correlating expression with treatment response and patient outcomes

  • Developing standardized IHC protocols for clinical applications

• Mechanistic studies:

  • Investigating MED28's role in "tumorigenesis," particularly the "med28-mediated regulatory network"

  • Mapping protein-protein interactions to identify "downstream targets"

  • Exploring connections between MED28's transcriptional and signaling functions

• Therapeutic applications:

  • Identifying small molecules that modulate MED28 function

  • Developing targeted therapies for cancers with MED28 overexpression

  • Using MED28 antibodies for targeted drug delivery approaches